Evaluation of Adverse Reactions and Clinical Rational Use of Anti-tumor Paclitaxel

Abstract

Objective. To study adverse reactions and clinical rational use of paclitaxel. Methods . Review and analyzed clinical data of 50 cases cancer patients treated in our hospital from January 2017 to December 2018. All cases were treated with paclitaxel only or in combination with other drugs. Monitor incidence of adverse reactions after treatment and analyze value of rational drug use. Results . Among 50 cases treated with paclitaxel, 47 (94.00%) had myelosuppression, 44 (88.00%) had alopecia, 32 (64.00%) had gastrointestinal reaction, 27 (54.00%) had hand and foot numbness, 18 (36.00%) had edema, 16 (32.00%) had liver toxicity, 15 (30.00%) had neurotoxicity, 7 (14.00%) had allergic reaction, and 5 (10.00%) had joint and muscle pain, 5 (10.00%) cases of blood system, 3 (6.00%) cases of renal toxicity, 2 (4.00%) cases of cardiac toxicity, 2 (4.00%) cases of fever and other adverse reactions. Conclusion . Paclitaxel is common anti-tumor drug, but its safety is not high. Therefore, it is necessary to use drugs carefully, control administration time strictly, and take preventive measures before treatment to reduce its incidence of adverse reactions.